OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced that ImmunoGen, Inc., a biotechnology company developing targeted anticancer therapeutics, has been added to its diverse and growing client portfolio. ImmunoGen chose Cytovance for process development, cell banking, and cGMP manufacturing of a proprietary ImmunoGen antibody. “We are very pleased to partner with ImmunoGen and provide manufacturing excellence to their products,” said Darren Head President and CEO of Cytovance Biologics. “Our relationship with ImmunoGen is an excellent example of our business model, value, services and state-of-the-art facilities.”
